Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, Jolson D, Amundson K, Buckley T, Lohse D, Lin A, Burrascano C, Ibanez C, Kasahara N, Gruber HE, Jolly DJ.

Mol Ther. 2012 Sep;20(9):1689-98. doi: 10.1038/mt.2012.83. Epub 2012 May 1. Erratum in: Mol Ther. 2013 Feb;21(2):494.

2.

Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.

Huang TT, Parab S, Burnett R, Diago O, Ostertag D, Hofman FM, Espinoza FL, Martin B, Ibañez CE, Kasahara N, Gruber HE, Pertschuk D, Jolly DJ, Robbins JM.

Hum Gene Ther. 2015 Feb;26(2):82-93. doi: 10.1089/hum.2014.100. Epub 2015 Jan 19.

3.

Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.

Takahashi M, Valdes G, Hiraoka K, Inagaki A, Kamijima S, Micewicz E, Gruber HE, Robbins JM, Jolly DJ, McBride WH, Iwamoto KS, Kasahara N.

Cancer Gene Ther. 2014 Oct;21(10):405-410. doi: 10.1038/cgt.2014.38. Epub 2014 Oct 10.

4.

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.

Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvão da Silva AP, Lin AH, Valenta DT, Perez OD, Ibañez CE, Chen CI, Pettersson PL, Burnett R, Daublebsky V, Hlavaty J, Gunzburg W, Kasahara N, Gruber HE, Jolly DJ, Robbins JM.

Neuro Oncol. 2012 Feb;14(2):145-59. doi: 10.1093/neuonc/nor199. Epub 2011 Nov 9.

5.

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, Walbert T, Chu A, Das A, Diago OR, Gammon D, Gruber HE, Hanna M, Jolly DJ, Kasahara N, McCarthy D, Mitchell L, Ostertag D, Robbins JM, Rodriguez-Aguirre M, Vogelbaum MA.

Sci Transl Med. 2016 Jun 1;8(341):341ra75. doi: 10.1126/scitranslmed.aad9784.

PMID:
27252174
7.

Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine.

Stolworthy TS, Korkegian AM, Willmon CL, Ardiani A, Cundiff J, Stoddard BL, Black ME.

J Mol Biol. 2008 Mar 28;377(3):854-69. doi: 10.1016/j.jmb.2008.01.002. Epub 2008 Jan 11.

8.

Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

Twitty CG, Diago OR, Hogan DJ, Burrascano C, Ibanez CE, Jolly DJ, Ostertag D.

Hum Gene Ther Methods. 2016 Feb;27(1):17-31. doi: 10.1089/hgtb.2015.106. Epub 2015 Dec 1.

9.

Replicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinoma.

Lu YC, Chen YJ, Yu YR, Lai YH, Cheng JC, Li YF, Shen CH, Tai CK.

Oncol Rep. 2012 Jul;28(1):21-6. doi: 10.3892/or.2012.1789. Epub 2012 Apr 26.

PMID:
22552490
10.

Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.

Yamada S, Kuroda T, Fuchs BC, He X, Supko JG, Schmitt A, McGinn CM, Lanuti M, Tanabe KK.

Cancer Gene Ther. 2012 Mar;19(3):160-70. doi: 10.1038/cgt.2011.70. Epub 2011 Nov 11.

11.
12.

Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.

Huang TT, Hlavaty J, Ostertag D, Espinoza FL, Martin B, Petznek H, Rodriguez-Aguirre M, Ibañez CE, Kasahara N, Gunzburg W, Gruber HE, Pertschuk D, Jolly DJ, Robbins JM.

Cancer Gene Ther. 2013 Oct;20(10):544-51. doi: 10.1038/cgt.2013.51. Epub 2013 Aug 23.

PMID:
23969884
13.
14.

Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy.

Hidaka A, Hamaji Y, Sasaki T, Taniguchi S, Fujimori M.

Biosci Biotechnol Biochem. 2007 Dec;71(12):2921-6.

15.

Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression.

Dubois L, Dresselaers T, Landuyt W, Paesmans K, Mengesha A, Wouters BG, Van Hecke P, Theys J, Lambin P.

Br J Cancer. 2007 Mar 12;96(5):758-61. Epub 2007 Feb 20.

16.

Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus.

Kubo S, Takagi-Kimura M, Logg CR, Kasahara N.

Cancer Gene Ther. 2013 Dec;20(12):671-7. doi: 10.1038/cgt.2013.67. Epub 2013 Nov 8.

PMID:
24201868
17.

Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.

Wang D, Ruan H, Hu L, Lamborn KR, Kong EL, Rehemtulla A, Deen DF.

Cancer Gene Ther. 2005 Mar;12(3):276-83.

PMID:
15650767
18.

Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation.

Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB.

Blood. 1998 Jul 15;92(2):672-82.

19.

Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.

Yagiz K, Huang TT, Lopez Espinoza F, Mendoza D, Ibañez CE, Gruber HE, Jolly DJ, Robbins JM.

Neuro Oncol. 2016 Oct;18(10):1390-401. doi: 10.1093/neuonc/now089. Epub 2016 May 10.

20.

[Antitumor activity of the recombinant rClone30-CD/5-FC system].

Lu Z, Zhang TY, Han MM, Bai FL, Wu W, Tian GY, Ren GP, Li DS.

Yao Xue Xue Bao. 2013 Feb;48(2):261-8. Chinese.

PMID:
23672024

Supplemental Content

Support Center